AEON Biopharma (NASDAQ:AEON) vs. Synaptogenix (NASDAQ:TAOX) Critical Analysis

AEON Biopharma (NASDAQ:AEON) and Synaptogenix (NASDAQ:TAOX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Risk and Volatility

AEON Biopharma has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.

Institutional and Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 0.9% of AEON Biopharma shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares AEON Biopharma and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Synaptogenix	N/A	-240.92%	-150.03%

Analyst Recommendations

This is a summary of recent ratings and price targets for AEON Biopharma and Synaptogenix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	1	1	1	3.00
Synaptogenix	1	0	0	0	1.00

Valuation & Earnings

This table compares AEON Biopharma and Synaptogenix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	$5.04	0.21
Synaptogenix	N/A	N/A	-$12.77 million	($20.16)	-0.25

Synaptogenix is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

AEON Biopharma beats Synaptogenix on 7 of the 11 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.